MaxCyte Inc Asset Resilience Ratio
MaxCyte Inc asset resilience ratio. MaxCyte Inc (MXCT) has an Asset Resilience Ratio of 43.45% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MXCT days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of MaxCyte Inc (2018–2024)
Asset resilience ratio of MaxCyte Inc from 2018 to 2024. This chart shows how MaxCyte Inc's Asset Resilience Ratio has changed over time. Read MXCT current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down MaxCyte Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see MaxCyte Inc assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $92.75 Million | 43.45% |
| Total Liquid Assets | $92.75 Million | 43.45% |
Asset Resilience Insights
- Very High Liquidity: MaxCyte Inc maintains exceptional liquid asset reserves at 43.45% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
MaxCyte Inc Industry Peers by Asset Resilience Ratio
Compare MaxCyte Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Applied BioCode
TW:6598 |
Medical Devices | 9.75% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Radiant Innovation
TWO:3373 |
Medical Devices | 0.82% |
|
Impedimed Ltd
AU:IPD |
Medical Devices | 46.15% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
MaxCyte Inc Asset Resilience Ratio by Year (2018–2024)
MaxCyte Inc asset resilience ratio by year from 2018 to 2024. The table below shows the annual Asset Resilience Ratio data for MaxCyte Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 52.87% | $126.60 Million | $239.47 Million | +7.47pp |
| 2023-12-31 | 45.39% | $121.78 Million | $268.27 Million | -30.05pp |
| 2022-12-31 | 75.45% | $216.28 Million | $286.65 Million | +2.50pp |
| 2021-12-31 | 72.95% | $207.26 Million | $284.12 Million | +42.03pp |
| 2020-12-31 | 30.91% | $16.01 Million | $51.78 Million | +25.92pp |
| 2019-12-31 | 5.00% | $1.50 Million | $29.99 Million | -8.15pp |
| 2018-12-31 | 13.15% | $3.19 Million | $24.27 Million | -- |
About MaxCyte Inc
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based … Read more